Standard Guidance

Reach FDA_21_CFR_PART_820 readiness without rebuilding your policy programme

FDA 21 CFR Part 820 is the Quality System Regulation (QSR) governing medical device manufacturers selling in the US — covering design controls, document controls, purchasing controls, production + process controls, CAPA, complaint handling, servicing, statistical techniques + management responsibility. The Quality Management System Regulation (QMSR) final rule (published Feb 2024, effective 2 Feb 2026) harmonises QSR with ISO 13485:2016 by incorporating the standard by reference, replacing many QSR-specific requirements but preserving FDA-specific records, labelling + complaint elements. Enforced through FDA inspections, 483s + Warning Letters. Quick Policy maps FDA_21_CFR_PART_820 into the policy families, controls, and evidence your team needs — and keeps it current between audits.

FDA_21_CFR_PART_820
Supervisory
Mandatory In Scope
Annual or 365-day review cycle

FDA_21_CFR_PART_820

Framework

US

Jurisdiction

Supervisory

Assurance

365 days

Review cadence

FDA_21_CFR_PART_820 quick answer

FDA 21 CFR Part 820 — Quality System Regulation (QSR) sets the policy, control, and evidence expectations an organisation needs to demonstrate when FDA_21_CFR_PART_820 is in scope for US — and Quick Policy is the fastest way to turn those expectations into a defensible operating programme without months of consultant time.

Standard facts

Framework: FDA_21_CFR_PART_820

Authority: US Food and Drug Administration (FDA / CDRH)

Jurisdiction: US

View official source

Why FDA_21_CFR_PART_820 matters for your operating model

FDA_21_CFR_PART_820 doesn't just dictate document templates — it shapes which controls auditors test, what evidence they ask for, and which gaps surface first during diligence. Getting it wrong creates renewal slippage, audit findings, and stalled customer deals.

  • Issued by US Food and Drug Administration (FDA / CDRH) and primarily enforced in US.
  • Directly shapes policy families including Quality Management, Medical Device — these are the artefacts assessors open first.
  • Common artifacts include Policy.
  • Obligation model: Mandatory In Scope — meaning you need defensible reasoning for in-scope vs out-of-scope decisions, not just signed policies.

How Quick Policy helps you stand up FDA_21_CFR_PART_820

The platform turns FDA_21_CFR_PART_820 from a PDF of requirements into a live operating model — policies, training, evidence, and audit-export packs that update in lock-step when the standard or your business changes.

  • Adopt FDA_21_CFR_PART_820 once and Quick Policy seeds the right policy families (Quality Management, Medical Device) with applicability rationale your auditor can follow.
  • Common artifacts include Policy.
  • Review cadence is enforced at ~365 days so policies don't silently expire ahead of recertification.
  • Standard updates (FDA_21_CFR_PART_820 revisions, errata, regulator guidance) trigger an applicability re-check across your active policies — not a full rewrite.

Policy families commonly involved

Quality Management
Medical Device

Recommended artifacts and context

Policy

Industry tags: LIFE_SCIENCES

Obligation model: Mandatory In Scope

Coverage depth: Control Rich

How Quick Policy operationalizes FDA_21_CFR_PART_820

Turn standards context into drafting, review, training, and evidence workflows that are easier to maintain over time.

1

Capture Core Profile

6-8 minutes
Unlocks drafting with a verified organisational baseline.

Admins complete adaptive onboarding to establish operating model, risk posture, and compliance objectives.

2

Determine Applicable Standards

1-2 minutes
Prevents generic policies by grounding outputs in real obligations.

Standards applicability ranks obligations by industry, geography, services, and data profile.

3

Generate and Harmonise Policy

3-8 minutes
Creates review-ready drafts with quality diagnostics and provenance.

Three-pass generation drafts, repairs contradictions, and validates coverage before reviewer handoff.

4

Review and Approve

Team dependent
Maintains accountability and publication controls.

Approvers validate policy language, mappings, and obligations using structured workflow stages.

Need adjacent guidance?

Use these pages for broader platform, industry, or buying context around FDA_21_CFR_PART_820.

Get FDA_21_CFR_PART_820-ready without the consultant invoice

Start a guided preview — no card, no sales call. Adopt FDA_21_CFR_PART_820, draft your first aligned policy, and export an audit-ready evidence pack inside the trial.